

AACR Special Conference In Cancer Research
**Liquid Biopsy: From Discovery to
Clinical Implementation**
November 13-16 | San Diego, CA

AACR
American Association
for Cancer Research*

2404031E


POSTER LISTING

**Current as of October 15, 2024*

PROFFERED PRESENTATIONS

POSTER SESSION A

POSTER SESSION B



Proffered Presentations

PR001 The CTC RPL/RPS gene signature: Targeting translation and the cell cycle inversely affects CTC metabolism but not metastasis. Dario Marchetti, The University of New Mexico Comprehensive Cancer Center, Albuquerque, New Mexico.

PR002,A002 The clinical relevance of circulating tumor cell size in head and neck squamous cell carcinoma patients. Hyeongjung Woo, Department of New Biology, DGIST, Daegu, Republic of Korea.

PR003,B001 ctDNA release kinetics and fragmentation to monitor treatment response and resistance in esophageal adenocarcinoma. Alexandra Bartolomucci, Research Institute of the McGill University Health Centre, Montreal, Quebec, Canada.

PR004,B004 Biological insights into tissue-agnostic plasma cfDNA methylation signature for surveillance of head and neck tumor recurrence. Yulia Newton, Adela, Inc., Foster City, California.

PR005,A033 Leveraging mass cytometry for phenotyping CTCs in SCLC liquid biopsies: Tracking therapy resistance at a personalized level. Loukia G. Karacosta, MD Anderson Cancer Center, Houston, Texas.

PR006,A073 The potential of multi-cancer early detection screening for reducing cancer mortality. Chris Tyson, Exact Sciences Corporation, Madison, Wisconsin.


PR007,A048 Screening early detection of HPV-associated oropharynx cancers with multi-feature HPV whole genome sequencing liquid biopsy. Daniel L. Faden, Mass Eye and Ear, Massachusetts General Hospital, Harvard Medical School, Boston, Massachusetts.

PR008,B016 Genome-wide analyses of cfDNA fragmentomes for therapeutic monitoring of patients with pancreatic cancer. Carolyn A. Hruban, The Sidney Kimmel Comprehensive Cancer Center, Johns Hopkins University School of Medicine, Baltimore, Maryland.

PR009,B038 Application of Liquid Biopsy-RECIST (LB-RECIST) criteria to track metastatic colorectal cancer (mCRC) molecular response in first-line (1L) setting: findings from the PLATFORM-B study. Valentino Martelli, Hospital del Mar Research Institute, Barcelona, Spain.

PR010,B041 High purity CTC RNA sequencing identifies poor prognosis lineage states in castrate resistant prostate cancer. Marina N. Sharifi, University of Wisconsin-Madison, Madison, Wisconsin.

PR011 Advance prostate cancer detection through epigenomic profiling of cell-free DNA. Mohamed Adil, University of Washington, Seattle, Washington.



PR012 A novel plasma-based epigenomic assay for comprehensive profiling of cancerous and inflammatory disease states. Carl Barrett, Precede Biosciences, Boston, Massachusetts.

PR013,A063 Highly accurate detection of early-stage colorectal cancer using tumor and immune extracellular vesicles biomarkers. Todd Hembrough, Nexosome Oncology, Durham, North Carolina.

PR014 Robust disease monitoring using CSF liquid biopsies collected from children undergoing cellular therapy for malignant central nervous system tumors. Anna Kostecka, St. Jude Children's Research Hospital, Memphis, Tennessee.

PR015 Novel digital PCR ctDNA monitoring assay evaluating exceptional responders to combination immune-oncology (IO) therapy. Daniel Stetson, AstraZeneca, Waltham, Massachusetts.


PR016,B067 Dynamic chromatin landscapes of colorectal cancer development and cell-free DNA fragmentation. Nicholas A. Vulpescu, Johns Hopkins University School of Medicine, Baltimore, Maryland.

PR017,B051 A T-cell signature in circulating cell-free DNA at time of diagnosis predicts response to checkpoint inhibition. Benjamin Schuster-Boeckler, Ludwig Cancer Research, University of Oxford, Oxford, United Kingdom.

PR018,B052 Plasma proteomic biomarkers reveal biological insights about the tumor microenvironment in melanoma patients after PD1 blockade. Samuel J. Wright, Broad Institute of MIT and Harvard, Cambridge, Massachusetts.

PR019,B055 Transfer learning for accurate tissue of origin classification from cfDNA methylation. Shiva Farashahi, Harbinger Health, Cambridge, Massachusetts.

PR020,B060 A novel framework for epigenome-dependent multimodal fragment-signature analysis reveals insights into cell-free DNA generation in cancer. Yoo-Na Kim, Harvard Medical School, Boston, Massachusetts.



Poster Session A
Thursday, November 14
5:15 p.m.-7:15 p.m.

A001 Analytical validation of a novel multiomic metastatic breast cancer liquid biopsy test that combines ctDNA analysis with CTC HER2-ultralow and ER co-expression, as well as single-cell chromosomal instability. David Bourdon, Epic Sciences, San Diego, California.

A003 CD45 positive circulating tumor cells as a prognostic marker in prostate cancer. Hyeongjung Woo, Department of New Biology, DGIST, Daegu, Republic of Korea.

A004 Full spectrum isolation technique-based dual circulating rare cells analysis to maximize early cancer diagnosis. Hyeongjung Woo, Department of New Biology, DGIST, Daegu, Republic of Korea.

A005 Microbind Affinity Blood Filter platform technology with affinity for heparan sulfate rapidly removes circulating epithelial tumor and cancer stem cells while downregulating VEGF A in patients with advanced and refractory solid tumors. Sanja Ilic, ExThera, San Diego, California.

A006 Development of a circulating tumor cell-derived cancer organoid platform for drug screening against metastatic tumors and longitudinal monitoring of drug resistance. Shian-Jiun Shih, Cellentia, Inc., Foster City, California.


A007 Transient elevation of ctHPVDNA in human papilloma virus-mediated oropharynx squamous cell carcinoma patients following diagnostic surgical procedures. Hlu Vang, Stanford University, Stanford, California.

A008 Adaptive immune receptor repertoire characterization highlights the importance of interplay between B and T cells in disease progression. Hossein Asgharian, Roche Diagnostics Solutions, Santa Clara, California.

A009 Integrative multi-omic analysis of extracellular vesicle transcriptomics profiling combined with cfDNA methylation reveals improved stratification of low-risk and high-risk prostate cancer patients in urine-based liquid biopsy. Sudipto K. Chakraborty, Exosome Diagnostics, a Bio-Techne brand, Waltham, Massachusetts.

A010 Biofluid-Ensemble Analysis through Multi-modal Spectroscopy (BEAMS): A deep learning architecture for rapid early-stage liquid biopsy cancer diagnostics. Kwan Lun Chiu, University of California, Davis, California.

A011 Identifying surface biomarkers from colorectal cancer-derived extracellular vesicles using a bead-based approach. Jessica Debattista, University of Malta, Malta, Malta.



A012 Analytical validation of a cfDNA-based fragmentomic profiling assay for the detection and quantification of 14 HPV types in cervical cancer. Catherine D.V. Fitz, Naveris, Inc., Waltham, Massachusetts.

A013 Quality control of the biobanked matched tissue - blood samples for the development of diverse liquid based molecular assays. Zoran Gatalica, Reference Medicine, Scottsdale, Arizona.

A014 A methylation state specific targeted background depletion technique for enrichment of ctDNA fraction. Sarah Falotico, Harbinger Health, Cambridge, Massachusetts.

A015 Validation of a cancer early-detection assay on liquid biopsies using DNA methylation. Ekaterina Gracheva, Hologic Diagenode, Denville, New Jersey.

A016 Early pancreatic cancer detection using extracellular vesicle DNA methylation signatures in blood. Hongzhang He, Captis Diagnostics, Pittsburgh, Pennsylvania.

A017 High-throughput microfluidic enrichment of circulating tumor cells from entire diagnostic leukapheresis for comprehensive liquid biopsy. Shih-Bo Huang, Massachusetts General Hospital Cancer Center and Harvard Medical School, Charlestown, Massachusetts.

A019 Analytical and clinical validation of HPV-SEQ, an NGS-based liquid biopsy platform for detection and quantification of human papilloma virus circulating tumor DNA. Samaneh Eickelschulte, Sysmex-Inostics, Hamburg, Germany.

A020 Enhanced cell-free RNA (cfRNA) recovery for liquid biopsy applications: Comparative analysis using controlled RNA samples for early and advanced cancer detection. Nafiseh J. Jafari, nRichDX, Irvine, California.

A021 Analytical platform to validate microRNA cancer biomarkers. Anastassia Kanavarioti, Yenos Analytical LLC, El Dorado Hills, California.


A022 Novel technology affords real-time PCR the sensitivity required for minimal residual disease monitoring. Sarah Kane, GT Molecular, Fort Collins, Colorado.

A023 Advancing RNA liquid biopsy technology via long-read sequencing. Daniel H. Kim, University of California, Santa Cruz, California.

A024 Evaluating the effect of plasma-related preanalytical variables on the robustness of the liquid biopsy early CRC detection Signal-C assay. Kristi Kruusmaa, Universaldx d.o.o., Ljubljana, Slovenia.

A025 Tumor fraction (TF) is associated with real-world progression-free survival (rwPFS) in advanced non-small-cell lung cancer (aNSCLC) patients treated with chemotherapy (chemo). Errin Lagow, Guardant Health, Inc., Palo Alto, California.

A026 A novel ddPCR detects hypermethylated RASSF1A in plasma of patients with pediatric Wilms tumor. Nathalie S.M. Lak, Princess Maxima Center, Utrecht, Netherlands.



A027 Systematic review of real-world adherence to blood-based laboratory tests for average-risk disease screening: potential implications for emerging colorectal cancer screening modalities. Quang Le, Exact Sciences Corporation, Madison, Wisconsin.

A028 Precise monitoring of osteosarcoma patients by noninvasive assessment of matrix metalloproteinases activities in plasma extracellular vesicles. Junseok Lee, University of California, Los Angeles, California.

A029 Novel high-purity CTC isolation technology for downstream analysis: A “Cell-Circuit” magnetophoretic-microfluidic hybrid device. Chanhee Lee, LMNTIC Biotech Co., Ltd., Seoul, Republic of Korea.

A030 Rapid extraction and detection of extracellular vesicle-derived PD-L1 in a microfluidic platform. Yuguang Liu, Mayo Clinic, Rochester, Minnesota.

A031 Harnessing the potential of circulating tumour cells for precision diagnostics via multiplexed imaging of the levels and subcellular localisations of over 50 cell identity, state and signalling markers per cell. John G. Lock, The University of New South Wales, Sydney, New South Wales, Australia.

A032 Performance evaluation of a new protein stabilizing blood collection tube with a novel whole blood separation device for clinical plasma proteomics. Colin McDowell, Bidesix, Louisville, Colorado.

A034 Addressing the challenge of pre-analytical variables in circulating protein biomarker analysis for liquid biopsy. Rachel M. Miller, Streck LLC., La Vista, Nebraska.

A035 A real-time PCR method for the detection of cancer-specific methylation patterns in cfDNA. Emily Neaga, Harbinger Health, Cambridge, Massachusetts.

A036 Next gen liquid biopsy: Comprehensive analysis from a single tube of blood. Arturo B. Ramirez, RareCyte, Inc., Seattle, Washington.


A037 Improved liquid biopsy assay performance using novel highly accurate sequencing-by-binding (SBB) technology. Alexandra Sockell, PacBio, Menlo Park, California.

A038 Investigating PD-L1 status in circulating tumor cells isolated from blood samples of lung cancer patients. Morgan Spode, ANGLE plc, Guildford, United Kingdom.

A039 A sensitive tool for the detection of RNA modifications in blood samples. Gudrun Stengel, Alida Biosciences, San Diego, California.

A040 Using mitochondrial abundance in tumor-derived extracellular vesicles for pancreatic cancer screening. Dali Sun, University of Denver, Denver, Colorado.

A041 Detection of early-stage gastrointestinal cancers using micronuclei DNA from erythrocytes. Haobo Sun, Westlake University, Hangzhou, China.



A042 cfDNA collection and purification improved & simplified: Inexpensive at-home device reduces large volumes of urine to a cfDNA containing stable filter. Floyd E. Taub, aiGENE, Aurora, Colorado.

A043 Tumor-informed whole genome sequencing of ctDNA from lymph and plasma detects molecular residual disease in HPV-negative head and neck cancer patients. Wendy Winckler, Droplet Biosciences, Inc., Cambridge, Massachusetts.

A044 Utilizing breast cancer-specific micronuclei DNA features from erythrocytes for early detection of breast carcinoma. Xingyun Yao, Westlake University, Hangzhou, China.

A045 Evaluating the potential of micronuclei DNA from erythrocytes for early detection of colorectal cancer. Xingyun Yao, Westlake University, Hangzhou, China.

A046 Development of a scoring system to classify HER2 protein expression in circulating tumor cells through immunofluorescence following isolation using Parsortix® instruments. Alex Young, ANGLE plc, Guildford, United Kingdom.

A047 Detecting hypoxic circulating tumor cells (H-CTC) with a novel technique. Beatriz Zayas, Ana G. Méndez University, San Juan, Puerto Rico.

A049 Peritoneal tumor DNA as a prognostic biomarker in locally advanced gastroesophageal cancer: A pilot prospective cohort study. Zexi Allan, Peter MacCallum Cancer Center, Melbourne, Victoria, Australia.

A050 Early detection of liver cancer from diverse populations using cfDNA fragmentome and protein biomarkers. Daniel Bruhm C. Bruhm, Johns Hopkins Sidney Kimmel Cancer Center, Baltimore, Maryland.

A051 Identifying patterns of cell-free DNA associated with elevated risk of diffuse large B-cell lymphoma in adult dogs. Lauren E. Burt, University of Minnesota, Minneapolis, Minnesota.


A052 Circulating tumor DNA (ctDNA) in plasma and urine of renal cell carcinoma patients with localized disease. Dirce Maria Carraro, A.C. Camargo Cancer Center, Sao Paulo, Brazil.

A053 Liquid biopsy-based detection of triple negative breast cancer using DNA methylation biomarkers. Jocelyn Charlton, Harbinger Health, Cambridge, Massachusetts.

A054 Oncogenic functions of alternatively spliced MDM2-ALT2 isoform in retroperitoneal liposarcoma. Fernanda Costas C. de Faria, The Ohio State University, Columbus, Ohio.

A055 Tumor muscle invasion promotes tumor heterogeneity and normal muscle reprogramming. Anne E. Cress, University of Arizona Cancer Center, Tucson, Arizona.

A056 Performance of multi-biomarker class reflex testing in a prospectively-collected cohort. Frank Diehl, Exact Sciences Corporation, Madison, Wisconsin.



A057 Cancer-induced epigenomic changes in circulating immune cells enable breast, colorectal and lung cancer detection. Gulfem D. Guler, ClearNote Health, San Mateo, California.

A058 Tumour-associated myeloid cells expressing IL-10R2/IL-22R1 as a potential biomarker for diagnosis and recurrence of pancreatic ductal adenocarcinoma. So Young Kim, Institute of Biomedical Research, Yonsei University College of Medicine, Seoul, Republic of Korea.

A059 Serum EphA2 proteolytic fragment is a potent biomarker for diagnosing a very early stage of ductal pancreatic carcinoma. Naohiko Koshikawa, Department of Life Science and Technology, Tokyo Institute of Technology, Yokohama, Japan.

A060 Identification of tumour-specific variants from pleural effusion cell-free DNA as diagnostic markers of cancers affecting the lungs. Connie MacKinnon, University of the Highlands and Islands, Inverness, United Kingdom.

A061 A cost-effective two-step approach for multi-cancer early detection in general population. Mao Mao, SeekIn Inc., San Diego, California / Yonsei Song-Dang Institute for Cancer Research, Yonsei University, Seoul Republic of Korea.

A062 Seeing the unseen: Liquid biopsy from aqueous humor reveals retinoblastoma's molecular signature. Sophia H. Montigel, Hopp Children's Cancer Center, Heidelberg, Germany.

A064 Lung cancer screening adherence among participants in DETECT-A, the first prospective interventional trial of a multi-cancer early detection (MCED) blood test. Nickolas Papadopoulos, Johns Hopkins University, Baltimore, Maryland.


A065 Estimation of HPV16-induced cervical cancer cells in routine Thin-prep cytology samples of cancer patients. Srishty Raman, All India Institute of Medical Sciences, New Delhi, Delhi, India.

A066 Could ancestry play a role in cancer development? Insights from a risk assessment and early detection test of naturally occurring cancers in companion dogs. Ashley J. Schulte, University of Minnesota, Minneapolis, Minnesota.

A067 IncTransformer: Identifying novel prognostic biomarkers for pancreatic cancer using deep learning models. Shivali Singh, Gwinnett School of Mathematics, Science and Technology, Lawrenceville, Georgia.

A068 Evaluate the performance of FibraChek™ for non-invasive detection of hepatic fibrosis and hepatocellular carcinoma. Steven M. Smith, Cedars-Sinai Medical Center, Los Angeles, California.

A069 Effect of different voided urine sample storage time and temperature, and preservatives, on analysis with the multiplex bead-based Oncuria® bladder cancer immunoassay. Steven M. Smith, Cedars-Sinai Medical Center, Los Angeles, California.




A070 Diagnostic accuracy of Oncuria®-detect in the detection of upper tract urothelial tumors. Sunao Tanaka, Cedars-Sinai Medical Center, Los Angeles, California.

A071 Performance of the Oncuria®-Detect test for the evaluation of patients presenting with hematuria: Results from a real world clinical setting. Sunao Tanaka, Cedars-Sinai Medical Center, Los Angeles, California.

A072 Oncuria®-monitor, a non-invasive test for the detection of recurrent bladder cancer: Cross sectional performance evaluation from a multicenter study. Sunao Tanaka, Cedars-Sinai Medical Center, Los Angeles, California.

A074 Early detection of breast implant associated anaplastic large cell lymphoma by multiplex lateral flow assay of CD30 and IL-10. Peng Xu, University of Virginia, Charlottesville, Virginia.

A075 Circulating T-cell receptor repertoire analysis improves cancer early detection. Roman Yelensky, Serum Detect, Inc., Newton, Massachusetts.



Poster Session B
Friday, November 15
6:15 p.m.-8:15 p.m.

B002 Determination of tumor PSMA expression and response to Lutetium-PSMA in men with prostate cancer using a novel epigenomic liquid biopsy platform. Jacob E. Berchuck, Emory University School of Medicine, Atlanta, Georgia.

B003 Dogs with cancer have higher plasma exosome concentrations compared with healthy dogs in the COED (canine osteosarcoma early detection) study. Kelly M. Makielski, University of Minnesota, Minneapolis, Minnesota.

B005 Investigating distinct methylation signatures characteristic of breast cancer subtypes in residual disease via cell free DNA methylation. Amber Alley, Georgetown University, Washington, District of Columbia.

B006 Qualitative research study on the use of minimal residual disease as an intermediate endpoint in multiple myeloma clinical trials in Saudi Arabia. Albandari A. Alnasser, Saudi Food and Drug Authority, Riyadh, Saudi Arabia.

B007 A qualitative research study on hematology and oncology consultants' experiences and opinions on using minimal residual disease (MRD) as a fast-track approval endpoint in early-phase clinical trials in multiple myeloma in Saudi Arabia. Albandari A. Alnasser, Saudi Food and Drug Authority, Riyadh, Saudi Arabia.


B008 Evaluating ctDNA as a risk-stratifying biomarker in non-metastatic triple-negative breast cancer treated with neoadjuvant chemotherapy. Dirce Maria Carraro, A.C. Camargo Cancer Center, Sao Paulo, Brazil.

B009 Individualized-tumor-informed panel approach enables ultra-sensitive ctDNA-based minimal residue disease monitoring for high-risk pediatric cancers. Wenhan Chen, Children's Cancer Institute, Sydney, New South Wales, Australia.


B010 Prognostic value of circulating tumor cells in stage III and IV melanoma: A systematic review and meta-analysis. Jennifer H. Chen, University of Texas MD Anderson Cancer Center, Houston, Texas.

B011 Circulating tumor DNA profiling in colorectal cancer to detect guideline-based targeted mutations at a Quebec health care centre. Monyse de Nobrega, McGill University, Montreal, Quebec, Canada.

B012 M-PACT: Methylation-based predictive algorithm for CNS tumor liquid biopsies. Tom T. Fischer, Hopp Children's Cancer Center, Heidelberg, Germany.



- B013 An mDETECT assay for monitoring treatment response in metastatic breast cancer patients.** Keira Frosst, Queen's University, Kingston, Ontario, Canada.
- B014 Prospective analysis of circulating tumor cell dynamics during preoperative radiotherapy in locally advanced breast cancer.** Chelain R. Goodman, University of Texas MD Anderson Cancer Center, Houston, Texas.
- B015 CSF liquid biopsies reveal disease status and resistance mechanisms in children undergoing targeted therapy for malignant brain tumors.** Katie Han, St. Jude Children's Research Hospital, Memphis, Tennessee.
- B017 MicroRNA and proteomic analyses of plasma extracellular vesicles detect diffuse large B-cell lymphoma.** Arthur A. Lee, University of Kansas Medical Center, Kansas City, Kansas.
- B018 Plasma-based circulating tumor tissue modified viral (TTMV)-HPV DNA for detection of recurrent HPV-driven anal cancer.** Shane Lloyd, University of Utah School of Medicine, Salt Lake City, Utah.
- B019 Clinical and molecular correlates of circulating tumor DNA (ctDNA) dynamics in breast tumors resistant to neoadjuvant therapy (NAT).** Mark Jesus M. Magbanua, University of California, San Francisco, California.
- B020 A blood-based multi-omics test for early evaluation of lymphoma treatment effectiveness.** Mao Mao, SeekIn Inc., San Diego, California / Yonsei Song-Dang Institute for Cancer Research, Yonsei University, Seoul Republic of Korea.
- B021 tRNA fragments extracted from patient plasma extra cellular vesicles display potential as biomarkers for high-grade glioma.** Thomson R. Phinney, Dalhousie University, Halifax, Nova Scotia, Canada.
- B022 Immediate post-treatment detection of minimal residual disease in HPV-driven oropharyngeal cancer is associated with high risk of recurrence.** Scott A. Roof, Icahn School of Medicine at Mount Sinai, New York, New York.
- B023 Cell-free HPV-DNA dynamics during induction chemotherapy and response-stratified de-escalation in viral-mediated oropharyngeal cancer.** Ari Rosenberg, University of Chicago, Chicago, Illinois.
- B024 Personalized tumor-informed circulating tumor (ct) DNA for advanced thyroid carcinoma.** Kartik Sehgal, Dana-Farber Cancer Institute, Boston, Massachusetts.
- B025 Monitoring response to immunotherapy in lung cancer using cell-free DNA fragmentomes.** Zachary L. Skidmore, Delfi Diagnostics Inc., Baltimore, Maryland.
- B026 Glioblastoma multiforme disseminates outside the central nervous system.** Pavel Stejskal, Institute of Molecular and Translational Medicine, Faculty of Medicine and Dentistry, Czech Advanced Technology and Research Institute, Palacky University and University Hospital, Olomouc, Czech Republic.



B027 Combining total cell-free DNA (cfDNA) and circulating tumor (ctDNA) to enhance the clinical sensitivity of ddPCR assays to detect minimal residual disease (MRD) in stage IIIB/C/IV melanoma patients on adjuvant immunotherapy in CheckMate 238.

Mahrukh M. Syeda, NYU Grossman School of Medicine, New York, New York.

B028 Analytical validation of tumor-informed whole genome sequencing analyses for detection of molecular residual disease in solid tumors. Kaitlin Victor, Labcorp Oncology, Baltimore, Maryland.

B029 Ultra-sensitive molecular residual disease detection through whole genome sequencing with single-read error correction. Li Weng, AccuraGen, San Jose, California.

B030 Advancing precision management in retinoblastoma via aqueous humor liquid biopsy: A case of TP53 and MDM4 alterations. Liya Xu, Children's Hospital Los Angeles, Los Angeles, California.

B031 Immune cell composition in surgical drain fluid as a novel prognostic marker in head and neck squamous cell carcinoma. Zhongping Xu, UPMC, Pittsburgh, Pennsylvania.

B032 Genome-wide 5-hydroxymethylation mapping in cell-free DNA to characterize the epigenetic differences in minimal residual disease of multiple myeloma. Zhou Zhang, Northwestern University, Chicago, Illinois.

B033 Towards magnetic resonance microscopy for liquid biopsy in cancer therapy monitoring. Karl Dustin Briegel, Technical University of Munich, Munich, Germany.

B034 Prevalence and implication of aflatoxin B1 expression in colon cancers diagnosed in Southern Nigeria. Chiagoziem Moral Delu-mozie, Nnamdi Azikiwe University, Nnewi, Abia, Nigeria.


B035 Detection and monitoring of translocation renal cell carcinoma via epigenomic profiling of cell-free DNA. Simon Garinet, Dana Farber Cancer Institute, Boston, Massachusetts / Université Paris Cité, Paris, France.

B036 Pathway repression in progression on osimertinib therapy in NSCLC via a comprehensive genomic and epigenomic circulating tumor DNA (ctDNA) assay. Aaron Hardin, Guardant Health, Inc., Palo Alto, California.

B037 Disks large-associated protein 5 (DLGAP5) is a putative prognostic biomarker for intraductal papillary mucinous neoplasm (IPMN) of pancreas. Radoslav Janostiak, First Faculty of Medicine, Charles University, Prague, Czech Republic.

B039 Clinical liquid biopsy testing for detecting actionable genomic alterations in children and young adults with advanced solid tumors. Holly J. Roberts, Boston Children's Hospital, Boston, Massachusetts.

B040 Cell-free DNA captures inter- and intra-patient heterogeneity in advanced bladder cancer. Samantha L. Schuster, Fred Hutchinson Cancer Center, Seattle, Washington.



B042 Molecular assessment of cell surface targets using integrated circulating tumor cell (CTC) RNAseq and single CTC phenotyping. Jamie M. Sperger, University of Wisconsin-Madison, Madison, Wisconsin.

B043 Molecular profiling of serially collected cerebrospinal fluid uncovers therapy-resistant subclones in recurrent leptomeningeal metastatic disease. Yingqi Zhang, University of Utah, Salt Lake City, Utah.

B044 Fragmentomic features of cell-free DNA predict late-stage melanoma treatment benefit and survival. Aaron B. Beasley, Edith Cowan University, Joondalup, Western Australia, Australia.

B045 The impact of smoking status on the genomic landscape of lung squamous cell carcinoma. Sahil Garg, Luminis Health, Annapolis, Maryland.

B046 Methylation based circulating tumor DNA serial monitoring correlates with immunotherapy response in non-small cell lung cancer. Hatim Husain, University of California, San Diego, California.

B047 Monitoring treatment response and toxicity in BRAF V600-mutant metastatic melanoma with circulating cell-free DNA. Sidharth S. Jain, Lombardi Comprehensive Cancer Center, Georgetown University, Washington, District of Columbia.

B048 Microfluidic isolation of immune cell-derived extracellular vesicles in head and neck cancer patients on immune-checkpoint blockade. Andrew R. Levy, Massachusetts General Hospital Cancer Center, Boston, Massachusetts.

B049 Validation of the PGDx elio™ plasma complete for comprehensive genomic profiling of solid tumors through liquid biopsy with Epic Sciences. Cynthia Maddox, Labcorp Oncology (PGDx), Baltimore, Maryland.


B050 Frequent monitoring of NSCLC immunotherapy using an mDETECT liquid biopsy reveals unexpected complexity and opportunities. Christopher R. Mueller, Queen's University, Kingston, Ontario, Canada.

B053 NucAE: Autoencoder-based enhancement of nucleosome occupancy signals from low-coverage cfDNA sequencing. Zsolt Balázs, University of Zurich, Zurich, Switzerland.


B054 Using FRAGILE score to capture context-dependent cfDNA fragmentation patterns for inference on their tissues-of-origin. Subhajyoti De, Rutgers, The State University of New Jersey, New Brunswick, New Jersey.

B056 Towards a generalized machine learning model for Raman spectroscopy-based liquid biopsy in cancer screening using self-supervised learning. Yifei Gu, University of California, Davis, California.

B057 Base-error model (BEM) for improved detection of ctDNA in lymph samples of HPV-negative head and neck cancer patients. Zhuosheng Gu, Droplet Biosciences, Inc., Cambridge, Massachusetts.



- B058 Novel machine learning lung cancer classifier shows significant correlation with cancer-specific fragmentomics features.** Carlos Guzman, Genece Health, San Diego, California.
- B059 Assessment of ctDNA analysis methods using high purity ctDNA from the aqueous humor of retinoblastoma eyes.** Nikki Higa, USC Michelson Center for Convergent Biosciences, Los Angeles, California.
- B061 Assessing saliva for cancer biomarker discovery: A liquid biopsy approach.** Srinivas V. Koduru, Wren Laboratories LLC, Branford, Connecticut.
- B062 Transcriptomic analysis of whole blood samples from prostate cancer patients: A comparative study of patients from geographically diverse populations.** Srinivas V. Koduru, Wren Laboratories LLC, Branford, Connecticut.
- B063 DiMMER: A robust computational pipeline for Differential Methylation Marker Evaluation in R of cell-free DNA fragments.** Arthur P. McDeed, Georgetown Lombardi Comprehensive Cancer Center, Washington, District of Columbia.
- B064 Prevalence and clinical relevance of clonal hematopoiesis in metastatic urologic malignancies.** Asli D. Munzur, Vancouver Prostate Centre, Vancouver, British Columbia, Canada.
- B065 Fabrica™: A large-scale data simulation platform isolates tumor signal from cell-free DNA and improves tissue of origin prediction accuracy.** Kade Pettie, Harbinger Health, Cambridge, Massachusetts.
- B066 Analytical validation of a multiplexed CTC-mRNA assay for androgen receptor pathway inhibitors.** Jennifer L. Schehr, University of Wisconsin-Madison, Madison, Wisconsin.
- B068 Inferring enhancer activity from cell-free DNA fragmentation patterns.** Alexis Yang, Dana-Farber Cancer Institute, Boston, Massachusetts.
- B069 Spatial and single-cell proteomic landscaping of the hypoxic microenvironment in glioblastoma.** Shreya Gandhi, Princess Margaret Cancer Research Tower, Toronto, Ontario, Canada.
- B070 Dissecting EV dynamics in the sequestration of doxorubicin from breast cancer cells.** Sina Halvaei, University of British Columbia, Vancouver, British Columbia, Canada.
- B071 Identifying the clinical utility of CSF as a source of liquid biopsy in pediatric brain tumors.** Liana Nobre, University of Alberta, Edmonton, Alberta, Canada.
- B072 Molecular targets of caffeine in breast cancer treatment: A network pharmacology approach.** Kingsley A. Osei, University of Ghana, Accra, Ghana.
- B073 Leveraging micronuclei DNA from erythrocytes for early detection of hepatocellular carcinoma.** Haobo Sun, Westlake University, Hangzhou, China.



AACR Special Conference In Cancer Research
**Liquid Biopsy: From Discovery to
Clinical Implementation**
November 13-16 | San Diego, CA

AACR
American Association
for Cancer Research*

2404031E

B074 Intrinsic subtypes in Ethiopian breast cancer patients: Implications for better care.
Zelalem Desalegn Woldesonbet, Addis Ababa University, Addis Ababa, Ethiopia.

B075 Detection of early gastric carcinoma by micronuclei DNA from erythrocytes.
Xingyun Yao, Westlake University, Hangzhou, China.